Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Latanoprost · 1 trial · 2 indications
Change from Baseline in Diurnal Mean IOP (mmHg) at Day 28 in the Study Eye -- ITT Population
| Arm | Type | Description |
|---|---|---|
| AKB-9778 4% QD + Latanoprost | EXPERIMENTAL | • AKB-9778 4% daily (AM) and placebo for ophthalmic solution daily (PM) plus latanoprost daily (PM) for 28 days |
| AKB-9778 4% BID + Latanoprost | EXPERIMENTAL | • AKB-9778 4% twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days |
| Placebo Twice Daily + Latanoprost | PLACEBO_COMPARATOR | • Placebo for AKB-9778 4% ophthalmic solution twice daily (AM \& PM) plus latanoprost daily (PM) for 28 days |
| Name | Type | Description |
|---|---|---|
| Latanoprost ophthalmic solution | DRUG | Latanoprost opthalmic solution to be dosed once daily |
| AKB-9778 4% | DRUG | Razuprotafib opthalmic solution |
| Placebo | DRUG | placebo for razuprotafib opthalmic solution |
Key Inclusion Criteria: * Diagnosis of OAG or OHT in each eye (OAG in one eye and OHT in the fellow eye is acceptable) * Must be receiving treatment with a stable regimen of topical prostaglandin eyedrop for a minimum of 2 weeks prior to the Screening Visit; may be taking one additional IOP lowerin...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |
Latanoprost is a small molecule being developed by EyePoint, Inc. for the treatment of ocular hypertension. It is an investigational therapy that has been studied in a Phase 2 clinical trial. The drug is intended to lower elevated intraocular pressure in patients with ocular hypertension.
Latanoprost is a prostaglandin analog that works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. It targets the prostaglandin F2-alpha receptor, which is involved in regulating fluid drainage in the eye. This mechanism is relevant for treating ocular hypertension.
Latanoprost is being developed by EyePoint, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol EYPT. The company is conducting clinical research to evaluate the drug's efficacy and safety for ocular hypertension.
Latanoprost is in Phase 2 clinical development for ocular hypertension. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is investigational and has not yet been approved by regulatory authorities.
Latanoprost has been studied in a Phase 2 clinical trial with the identifier NCT04405245. This trial assessed the efficacy, safety, and tolerability of AKB-9778 ophthalmic solution as an adjunct to Latanoprost in patients with ocular hypertension or open angle glaucoma. The study enrolled 194 participants and was completed in the United States.
Latanoprost is not the same as AKB-9778. In the clinical trial NCT04405245, AKB-9778 was studied as an adjunct therapy to Latanoprost. Latanoprost is the primary drug being developed by EyePoint, Inc., while AKB-9778 is a separate investigational agent used in combination with it.